Cenderitide, is a novel chimeric natriuretic peptide(NP) developed by the Mayo Clinic as a potential treatment for heart failure. As a chimeric peptide, cenderitide is a single-chemical entity that possesses two separate functions. Specifically, this novel peptide was engineered unlike native NPs to uniquely co-activate the two particulate guanylyl cyclase (pGC) receptors (pGC-A and pGC-B) so as to take advantage of distinct receptor mediated actions through 3′5′ cyclic guanosine monophosphate (cGMP). The rationale for its design was to achieve the renal-enhancing and antifibrotic properties of dual receptor activation, but without clinically significant hypotension.